AR098740A1 - Análogos del péptido exendina-4 - Google Patents

Análogos del péptido exendina-4

Info

Publication number
AR098740A1
AR098740A1 ARP140104639A ARP140104639A AR098740A1 AR 098740 A1 AR098740 A1 AR 098740A1 AR P140104639 A ARP140104639 A AR P140104639A AR P140104639 A ARP140104639 A AR P140104639A AR 098740 A1 AR098740 A1 AR 098740A1
Authority
AR
Argentina
Prior art keywords
ser
amino acid
acid residue
residue selected
gln
Prior art date
Application number
ARP140104639A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR098740A1 publication Critical patent/AR098740A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere a derivados de exendina-4 y a su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, que incluyen diabetes y obesidad, además de reducción de la ingesta excesiva de alimentos. Reivindicación 1: Un compuesto peptídico que tiene la fórmula (1): R¹-Z-R² (1) en donde Z es un resto de péptido que tiene la fórmula (2): His-X²-X³-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Leu-Asp-Glu-Gln-X¹⁸-Ala-X²⁰-X²¹-Phe-Ile-Glu-Trp-Leu-Ile-X²⁸-Gly-Gly-Pro-X³²-Ser-Gly-AIa-Pro-Pro-Pro-Ser (2) X² representa un residuo de aminoácido seleccionado de Ser, D-Ser y Aib, X³ representa un residuo de aminoácido seleccionado de Gln y His, X¹⁸ representa un residuo de aminoácido seleccionado de Leu y His X²⁰ representa un residuo de aminoácido seleccionado de His, Arg, Lys, (S)MeLys y Gln, X²¹ representa un residuo de aminoácido seleccionado de Asp y Glu, X²⁸ representa un residuo de aminoácido seleccionado de Lys, Ser y Ala, X³² representa un residuo de aminoácido seleccionado de Ser y Val, R¹ representa NH₂, R² representa OH o NH₂, o una sal o solvato del mismo.
ARP140104639A 2013-12-13 2014-12-12 Análogos del péptido exendina-4 AR098740A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306716 2013-12-13

Publications (1)

Publication Number Publication Date
AR098740A1 true AR098740A1 (es) 2016-06-08

Family

ID=49883000

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104639A AR098740A1 (es) 2013-12-13 2014-12-12 Análogos del péptido exendina-4

Country Status (5)

Country Link
US (1) US20150166625A1 (es)
EP (1) EP3080151A1 (es)
AR (1) AR098740A1 (es)
TW (1) TW201609798A (es)
WO (1) WO2015086732A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017112889A1 (en) 2015-12-23 2017-06-29 The Johns Hopkins University Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CA3086918A1 (en) * 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
JP7434169B2 (ja) 2018-04-10 2024-02-20 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 固相からの固相結合ペプチドの切断方法
MX2020010715A (es) 2018-04-10 2021-01-08 Sanofi Aventis Deutschland Sintesis de lixisenatida con taponamiento.
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
UY38249A (es) 2018-05-30 2019-12-31 Sanofi Sa Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134340A2 (en) * 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
EA200870575A1 (ru) * 2006-05-26 2009-08-28 Амилин Фармасьютикалз, Инк. Композиции и способы лечения застойной сердечной недостаточности
EP2952202B1 (en) * 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
NZ589847A (en) * 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists

Also Published As

Publication number Publication date
US20150166625A1 (en) 2015-06-18
WO2015086732A1 (en) 2015-06-18
TW201609798A (zh) 2016-03-16
EP3080151A1 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
AR098740A1 (es) Análogos del péptido exendina-4
AR098739A1 (es) Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón)
AR105816A2 (es) Derivados de exendina-4 funcionalizada
AR098737A1 (es) Agonistas duales del receptor de glp-1 / gip
AR098736A1 (es) Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa)
AR099976A1 (es) Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
AR110300A1 (es) Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
AR091866A1 (es) Analogos del glucagon
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
PE20231639A1 (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1)
PE20151808A1 (es) Peptidos terapeuticos
PE20171058A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
BR112014023374A2 (pt) composições de peptídeos de glp-1 e preparação das mesmas
BR112016018548A2 (pt) composto, ácido, medicamento, e, uso de um composto.
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
PE20200606A1 (es) Composiciones solidas para administracion oral
AR110301A1 (es) Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
BR112015024659A8 (pt) formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
BR112017007138A2 (pt) composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto.
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico

Legal Events

Date Code Title Description
FB Suspension of granting procedure